New imaging agent could sharpen cancer detection
NCT ID NCT06977945
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new imaging agent called FL-091, which targets a protein (NTSR1) found on some cancer cells. Researchers will use it with PET or SPECT scans to see if it can better detect and stage cancers like head and neck, colorectal, and pancreatic cancer. About 100 adults with suspected or confirmed NTSR1-positive tumors will take part. The goal is to see how well the agent highlights tumors and where it goes in the body, laying groundwork for future targeted treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FL-091 (a radionuclide imaging agent)
What this could lead to
If successful, this could lead to a more accurate way to detect and stage certain cancers, potentially guiding better treatment decisions.
What could go wrong
This is an early diagnostic study with only 100 participants, so results may not apply to all patients. The imaging agent's effectiveness and safety are still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wuhan Union Hospital,China
RECRUITINGWuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact